Abstract
Fluvoxamine Mediates Specific, Early, and Delayed SARS-CoV-2 Protection through Antioxidant and Cytoprotective Pathways via Sigma-1 Receptor Agonism.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have